Fibrous dysplasia is a rare bone disorder characterized by the abnormal development of fibrous tissue in place of normal bone. There may not be specific companies exclusively focused on fibrous dysplasia, but various pharmaceutical and biotechnology companies may be involved in research and development related to bone disorders, including treatments that may have implications for fibrous dysplasia.
Positive Phase 3 results for denosumab (Amgen): April 2023 saw encouraging news with the FLEX trial demonstrating denosumab's effectiveness in reducing bone turnover and pain in FD patients. This could lead to a new treatment option for moderate-to-severe cases.
Clinical trials for gene therapy Several companies are actively investigating gene therapy approaches to treat FD, aiming to address the root cause of the condition. These therapies are still in early stages of development, but they hold potential for a long-term cure.
Expansion of research on targeted therapies Researchers are exploring the use of other targeted drugs like MEK inhibitors and Janus kinase (JAK) inhibitors for treating FD, potentially offering more personalized treatment options in the future.
FDA approval for denosumab (Xgeva) for treatment of FD: July 2023 approval in the US offers a new option for managing bone turnover and pain in FD patients with moderate to severe symptoms.
List of Fibrous Dysplasia Key Companies in the Market
Fibrous Dysplasia Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)